2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5884 A phase I trial of bispecific CD19/CD20-targeted chimeric antigen receptor (CAR) modified T cells with 4-1BB and mutated CD28 costimulatory domains in patients with relapsed or refractory (R/R) CD19+ hematologic malignancies (BCM)

Alex Niu, MD, Han Yu, PhD, MBBS2, Christopher Choi, PhD, MBA3, Meredith L. Stone, PhD4, Amelia Harper5, Matthew J. Cortese, MD, MPH6, Chelsea Peterson, DO7, Grant Schofield, MD, MSc (MED), FRCPC8, Brian C. Betts, MD9, Francisco Hernandez-Ilizaliturri, MD10, Marco Davila, MD, PhD11
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Background:

Since their introduction, CAR-T cell therapy has demonstrated high overall response rates (ORR) and has improved the overall survival (OS) of patients with R/R BCM. However, relapse within the first 12 months is as high as 61%, and post-CAR T-cell relapse is associated with poor prognosis, highlighting a need for more effective CAR T-cell therapies. Multiple factors negatively impact the efficacy of CAR T-cells. CD19 antigen loss has been observed in relapses post-CAR-T cell therapy, indicating this loss can affect the functionality of the CD19 CAR-T cells. Additionally, CD28 co-stimulation has been associated with increased susceptibility to T-cell exhaustion and decreased persistence compared with that of 4-1BB.

BBMUT06 (CD19/CD20 with 4-1BB and mutant CD28 costimulatory domain) is a novel, bispecific CAR T-cell product designed to mitigate antigen escape and enhance CAR T-cell cytotoxicity and persistence. Preclinical studies identified this configuration as the highest CAR expression level and CD4/CD8 ratios. Additionally, increased percentage of CAR central memory cells, secretions of interferon gamma, interleukin-2 and tumor necrosis factor-alpha, factors associated with improved CAR expansion, persistence, and cytotoxicity, were also observed. The CD28 domain contains YMNM and PRRP mutations, leaving only the PYAP subdomain to increase persistence and mitigate exhaustion associated with wild-type CD28. In-vivo mice studies with Raji CD19 tumor cells demonstrated BBMUT06 controlled tumor growth with increased CAR T-cells along with a corresponding decrease in CD19+ cells. Additionally, exhaustion-associated markers PD1 and CD39 were analyzed, with BBMUT06 demonstrating a lower frequency of PD1+CD39+ cells, supporting improved functional persistence.

Considering this data, we chose to investigate BBMUT06 in patients with R/R CD19+ BCM.

Study Design and Methods:

We designed an investigator-initiated, open-label, single-arm phase 1 trial at Roswell Park Comprehensive Cancer Center (clinicaltrials.gov: NCT07701889). The primary objective of this trial is to determine the safety, toxicity, and maximum tolerated dose (MTD) of BBMUT06 in patients with R/R BCM. Secondary objectives will assess the anti-tumor efficacy of BBMUT06, including progression-free survival, OS, ORR, complete response, and duration of response. Correlative studies evaluating B-cell markers, cytokines, T-cell subsets, etc., will be collected to evaluate acute and chronic effects of BBMUT06.

Inclusion criteria include patients > 12 age. Eligible subtypes include diffuse large b-cell lymphoma and high-grade B-cell lymphoma that are primary refractory or relapsed after > two prior lines of therapy; mantle cell lymphoma and secondary central nervous system (CNS) lymphoma > two prior lines of therapy; and B-cell acute lymphoblastic leukemia, chronic myeloid leukemia, and Burkitt lymphoma (BL) after > one line of therapy. Prior CD19-targeted therapy is permitted. CD19/CD20 expression must be confirmed by immunohistochemical staining or flow cytometry. Key exclusion criteria include impaired cardiac function, active autoimmune disease and graft-versus-host disease. Given limited adolescent access to CAR T-cell therapy, this trial includes collaboration with pediatric oncology. This phase I trial encompasses escalating doses of BBMUT06. All patients will receive lymphodepletion chemotherapy consisting of fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 from days -5 to -3, followed by a single BBMUT06 infusion on day 0. Four dose levels are planned: 3x105, 1x106, 3x106, and 1x107, with an optional de-escalation cohort level (1x105) without lymphodepletion in the event of severe toxicity at the initial dose level. Cohorts of three will be enrolled using a Bayesian Optimal Interval (BOIN) design, with a maximum sample size of 21 and a target dose-limiting toxicity (DLT) rate of 0.3 at the MTD (defined as the highest dose where minimal DLTs are observed). DLTs will be assessed within 30 days of BBMUT06 infusion to establish the phase two recommended dose. Toxicities will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version six.

Significance:

This study evaluates a novel CAR T-cell product for R/R BCM including subtypes with limited data regarding CAR T-cell usage, such as BL, secondary CNS lymphoma, and patients previously treated with CAR T. Clinical activation is anticipated for November/2026.
Alex Niu, MD: Abbvie - Honoraria; Genentech - Honoraria; ADC Therapeutics - Honoraria; Bristol Myers Squibb - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)